JP6424155B2 - 白血病を治療するための化合物および方法 - Google Patents
白血病を治療するための化合物および方法 Download PDFInfo
- Publication number
- JP6424155B2 JP6424155B2 JP2015500545A JP2015500545A JP6424155B2 JP 6424155 B2 JP6424155 B2 JP 6424155B2 JP 2015500545 A JP2015500545 A JP 2015500545A JP 2015500545 A JP2015500545 A JP 2015500545A JP 6424155 B2 JP6424155 B2 JP 6424155B2
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- cells
- compounds
- ref
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
- C07C49/563—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
RAは、任意に置換されていてもよい縮合アリール環を表し、
Rは、水素もしくはハロであるか、または、Rは、それぞれ任意に置換されていてもよい、アルキル、ヘテロアルキル、シクロアルキル、またはシクロヘテロアルキルを表し、
Xは、それぞれ任意に置換されていてもよい、アルキレン、アルケニレン、またはアルキニレンであり、
Yは、カルボン酸、エステル、またはアミドを形成する)
で表される少なくとも1種類のRef−1レドックス阻害剤またはその薬学的に許容される塩を有効量で投与するステップを含む、白血病の治療が必要な患者で白血病を治療する方法が提供される。
RAは、任意に置換されていてもよい縮合アリール環を表し、
Rは、水素もしくはハロであるか、または、Rは、それぞれ任意に置換されていてもよい、アルキル、ヘテロアルキル、シクロアルキル、もしくはシクロヘテロアルキルであり、
Xは、それぞれ任意に置換されていてもよい、アルキレン、アルケニレン、またはアルキニレンであり、
Yは、カルボン酸、エステル、またはアミドを形成する)
で表される少なくとも1種類の化合物またはその薬学的に許容される塩を、有効量で投与するステップを含む、患者における白血病を治療するための方法。
RAは、任意に置換されていてもよい縮合アリール環を表し、
Rは、水素もしくはハロであるか、または、Rは、それぞれ任意に置換されていてもよい、アルキル、ヘテロアルキル、シクロアルキル、もしくはシクロヘテロアルキルであり、
Xは、それぞれ任意に置換されていてもよい、アルキレン、アルケニレン、またはアルキニレンであり、
Yは、カルボン酸、エステル、またはアミドを形成する)
で表される化合物またはその薬学的に許容される塩である、使用方法。
RAは、任意に置換されていてもよい縮合アリール環を表し、
Rは、水素もしくはハロであるか、または、Rは、それぞれ任意に置換されていてもよい、アルキル、ヘテロアルキル、シクロアルキル、もしくはシクロヘテロアルキルを表し、
Xは、それぞれ任意に置換されていてもよい、アルキレン、アルケニレン、またはアルキニレンであり、
Yは、カルボン酸、エステル、またはアミドを形成する)
で表される少なくとも1種類の化合物またはその薬学的に許容される塩を含む、白血病を治療するための組成物。
Claims (5)
- 小児急性リンパ性白血病、乳児急性リンパ性白血病、T細胞性急性リンパ性白血病、再発急性リンパ性白血病、難治性急性リンパ性白血病、およびグルココルチコイド抵抗性急性リンパ性白血病からなる群から選択される白血病の治療のための組成物であって、3−[(5−(2,3−ジメトキシ−6−メチル 1,4−ベンゾキノイル)]−2−ノニル−2−プロペン酸(E3330)、またはその薬学的に許容される塩または溶媒和物を有効成分として含有する組成物。
- 前記組成物は、1種類以上の担体、希釈剤、もしくは賦形剤、または、これらの組み合わせをさらに含む、請求項1に記載の組成物。
- 前記E3330は、Ref−1レドックス機能の選択的阻害剤である、請求項1または2に記載の組成物。
- 1種類以上の抗白血病化学療法剤もしくは1種類以上の抗白血病酵素阻害剤、またはこれらの組み合わせをさらに含む、請求項1〜3のいずれか1項に記載の組成物。
- デキサメタゾン、ビンクリスチン、ドキソルビシン、およびメトトレキサートからなる群から選択された、少なくとも一つの付加的な化学療法剤をさらに含む請求項4に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261610722P | 2012-03-14 | 2012-03-14 | |
US61/610,722 | 2012-03-14 | ||
PCT/US2013/030748 WO2013138430A1 (en) | 2012-03-14 | 2013-03-13 | Compounds and methods for treating leukemia |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015511604A JP2015511604A (ja) | 2015-04-20 |
JP2015511604A5 JP2015511604A5 (ja) | 2016-03-10 |
JP6424155B2 true JP6424155B2 (ja) | 2018-11-14 |
Family
ID=49161751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015500545A Active JP6424155B2 (ja) | 2012-03-14 | 2013-03-13 | 白血病を治療するための化合物および方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US9315481B2 (ja) |
EP (1) | EP2825162B1 (ja) |
JP (1) | JP6424155B2 (ja) |
KR (1) | KR20140136436A (ja) |
CN (2) | CN109602734A (ja) |
AU (1) | AU2013232208B2 (ja) |
CA (1) | CA2865437A1 (ja) |
ES (1) | ES2689665T3 (ja) |
IL (1) | IL234273A (ja) |
MX (1) | MX356102B (ja) |
RU (1) | RU2672553C2 (ja) |
WO (1) | WO2013138430A1 (ja) |
ZA (1) | ZA201406172B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2013152626A (ru) * | 2011-05-26 | 2015-07-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | ХИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДУЕМЫХ Ape1 |
CA2986248C (en) * | 2015-05-21 | 2023-09-26 | Indiana University Research & Technology Corporation | Methods of targeting ape1/ref-1 to inhibit hypoxia signaling genes |
WO2018140286A1 (en) * | 2017-01-25 | 2018-08-02 | Indiana University Research And Technology Corporation | Prophylaxis and treatment of acute myeloid leukemia |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
KR20040034573A (ko) * | 2001-09-17 | 2004-04-28 | 다이이찌 산토리 파마 가부시키가이샤 | NF-κB 억제 작용을 하는 치환된 벤조산 유도체 |
RU2315043C2 (ru) * | 2002-06-28 | 2008-01-20 | Ниппон Синяку Ко., Лтд. | Амидное производное, фармацевтическая композиция и терапевтические средства на его основе |
FR2900150B1 (fr) * | 2006-04-25 | 2012-07-06 | Fluofarma | Composes de type 1,4-naphtoquinones, compositions les comprenant et utilisation de ces composes en tant qu'agent anti-cancereux |
US20100086544A1 (en) * | 2006-12-11 | 2010-04-08 | Mass Robert D | Compositions and methods for treating a neoplasm |
MX2010003315A (es) | 2007-09-26 | 2011-03-15 | Univ Indiana Res & Tech Corp | Derivados de benzoquinona e3330 en combinacion con agentes quimioterapeuticos para el tratamiento de cancer y angiogenesis. |
CN104666286A (zh) * | 2007-11-21 | 2015-06-03 | 印第安纳大学研究及科技有限公司 | 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成 |
WO2009095399A2 (en) * | 2008-02-01 | 2009-08-06 | Akinion Pharmaceuticals Ab | Pyrazine derivatives and their use as protein kinase inhbitors |
RU2013152626A (ru) | 2011-05-26 | 2015-07-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | ХИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОПОСРЕДУЕМЫХ Ape1 |
US20140128398A1 (en) | 2011-06-03 | 2014-05-08 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
-
2013
- 2013-03-13 EP EP13761860.9A patent/EP2825162B1/en active Active
- 2013-03-13 WO PCT/US2013/030748 patent/WO2013138430A1/en active Application Filing
- 2013-03-13 CN CN201811324380.9A patent/CN109602734A/zh active Pending
- 2013-03-13 MX MX2014010275A patent/MX356102B/es active IP Right Grant
- 2013-03-13 AU AU2013232208A patent/AU2013232208B2/en active Active
- 2013-03-13 RU RU2014141152A patent/RU2672553C2/ru not_active IP Right Cessation
- 2013-03-13 US US14/384,814 patent/US9315481B2/en active Active
- 2013-03-13 CN CN201380013870.6A patent/CN104244934A/zh active Pending
- 2013-03-13 CA CA2865437A patent/CA2865437A1/en not_active Abandoned
- 2013-03-13 KR KR20147024023A patent/KR20140136436A/ko not_active Application Discontinuation
- 2013-03-13 ES ES13761860.9T patent/ES2689665T3/es active Active
- 2013-03-13 JP JP2015500545A patent/JP6424155B2/ja active Active
-
2014
- 2014-08-21 ZA ZA2014/06172A patent/ZA201406172B/en unknown
- 2014-08-24 IL IL234273A patent/IL234273A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2865437A1 (en) | 2013-09-19 |
JP2015511604A (ja) | 2015-04-20 |
WO2013138430A1 (en) | 2013-09-19 |
MX2014010275A (es) | 2014-09-16 |
CN109602734A (zh) | 2019-04-12 |
KR20140136436A (ko) | 2014-11-28 |
RU2014141152A (ru) | 2016-05-10 |
ZA201406172B (en) | 2016-05-25 |
ES2689665T3 (es) | 2018-11-15 |
RU2672553C2 (ru) | 2018-11-16 |
CN104244934A (zh) | 2014-12-24 |
US9315481B2 (en) | 2016-04-19 |
EP2825162A1 (en) | 2015-01-21 |
IL234273A (en) | 2017-07-31 |
AU2013232208B2 (en) | 2017-04-27 |
MX356102B (es) | 2018-05-14 |
EP2825162B1 (en) | 2018-09-12 |
US20150018355A1 (en) | 2015-01-15 |
EP2825162A4 (en) | 2015-01-21 |
AU2013232208A1 (en) | 2014-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105481789B (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
JP6272982B2 (ja) | Ape1媒介疾患を処置するためのキノン化合物 | |
US20150292045A1 (en) | Alternative uses for hbv assembly effectors | |
AU2012258665A1 (en) | Quinone compounds for treating Ape1 mediated diseases | |
JP6424155B2 (ja) | 白血病を治療するための化合物および方法 | |
JP2014531402A5 (ja) | ||
JP2014531402A (ja) | 新規アニリン誘導体及びこれの用途(Novelanilinederivativesandusethereof) | |
EP3560914A1 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
US20140249312A1 (en) | [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer | |
NZ759233B2 (en) | Compositions and methods for modulating hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170118 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181022 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6424155 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |